TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24209408

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham whole-body vibration (SWBV)
Number of subjects: 17
Study: 21112536

Group type: EXPERIMENTAL
Intervention: Heat-killed Enterococcus faecalis cells inoculated into instrumented human root canals ex vivo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Extracted E. faecalis DNA incubated in various media (water, 10%-50% sera, and DNase)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cell-bound E. faecalis DNA
Number of subjects: 40
Study: 18817909

Group type: EXPERIMENTAL
Intervention: Cryotherapy by trained midwives
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Cryotherapy for CIN 1
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Cryotherapy for CIN 2 and CIN 3 combined
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 1068
Study: 15474694

Group type: EXPERIMENTAL
Intervention: Combined endurance/resistance training
Number of subjects: 27

Group type: COMPARATOR
Intervention: Untrained heart failure control group
Number of subjects: 27
Study: 11237061

Group type: EXPERIMENTAL
Intervention: Measurement of blast percentage on day 14 by an expert morphologist
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Detection of monoclonality on day 35
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: PCR-based measurement of MRD levels on days 14 and 35
Number of subjects: 38

Group type: COMPARATOR
Intervention: Measurement of blast percentage on day 14 by routine morphology
Number of subjects: 38

Group type: COMPARATOR
Intervention: Detection of monoclonality on day 14
Number of subjects: 38
Study: 9914666

Group type: EXPERIMENTAL
Intervention: Cognitive load applied to at-risk participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: No cognitive load
Number of subjects: 0
Study: 7918211

Group type: EXPERIMENTAL
Intervention: Therapeutic relationship
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Challenges to the therapeutic relationship
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Process of change
Number of subjects: 0
Study: 3347763

Group type: EXPERIMENTAL
Intervention: Talking
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Interactive (RISS)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study: 29097444

Group type: EXPERIMENTAL
Intervention: Monthly subcutaneous injections of 3.6 mg goserelin and continuous 60 mg raloxifene daily orally for 2 years
Number of subjects: 75

Group type: COMPARATOR
Intervention: Mammographic screening alone
Number of subjects: 75
Study: 27106573

Group type: EXPERIMENTAL
Intervention: Exposure in transport hub (2 hours)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Exposure in park (2 hours)
Number of subjects: 40
Study: 24673650

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 276
Study: 22818151

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percutaneous radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Permanent seed implantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 0
Study: 20185598

Group type: EXPERIMENTAL
Intervention: Model predictive control for dosing erythropoietin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard anemia management protocol (control)
Number of subjects: 60
Study: 18448978

Group type: EXPERIMENTAL
Intervention: Various vaccine candidates (live attenuated, conjugate, broad spectrum, proteosome-based)
Number of subjects: 163000000

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 163000000
Study: 16145407

Group type: EXPERIMENTAL
Intervention: Extended release oxybutynin (5 to 30 mg daily, individualized dosing)
Number of subjects: 420
Study: 11851607

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 242
Study: 10219185

Group type: EXPERIMENTAL
Intervention: Sonic toothbrush (Sonicare)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual brushing (control)
Number of subjects: 0
Study: 7930477

Group type: EXPERIMENTAL
Intervention: Glucose infusion (1 mg.kg‐1.min‐1) for 45 min
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Euglycemic insulin clamp (1 mU.kg‐1.min‐1) for 2 hours
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Splanchnic glucose uptake
Number of subjects: 13

Group type: COMPARATOR
Intervention: Basal insulin levels
Number of subjects: 13

Group type: COMPARATOR
Intervention: Net splanchnic glucose output
Number of subjects: 13

Group type: COMPARATOR
Intervention: Leg glucose uptake
Number of subjects: 13
Study: 3063718

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.15 mg/kg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.30 mg/kg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.60 mg/kg
Number of subjects: 19
Study: 31212100

Group type: EXPERIMENTAL
Intervention: Sustained Care (SusC)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 353
Study: 27936811

Group type: EXPERIMENTAL
Intervention: TeenDrivingPlan (TDP)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Practice diversity
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Parents' perceptions of adolescents' skill in comparison to peers
Number of subjects: 295
Study: 26222750

Group type: EXPERIMENTAL
Intervention: Metronidazole Vaginal Gel 1.3%
Number of subjects: 651

Group type: COMPARATOR
Intervention: Vehicle Gel
Number of subjects: 651
Study: 24397194

Group type: EXPERIMENTAL
Intervention: Pegylated interferon and ribavirin therapy for 24 weeks (genotypes 2 and 3) or 48 weeks (genotypes 1 and 4)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Prisoners with virus genotype 1
Number of subjects: 52
Study: 21512184

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 973

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 973
Study: 19115219

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF, 300 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lamivudine (LMV, 300 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination therapy (TDF/LMV)
Number of subjects: 21

Group type: COMPARATOR
Intervention: HBeAg-positive individuals
Number of subjects: 21
Study: 16681329

Group type: EXPERIMENTAL
Intervention: Two invitation letters
Number of subjects: 3144

Group type: EXPERIMENTAL
Intervention: One invitation letter plus a follow-up telephone call
Number of subjects: 3144

Group type: COMPARATOR
Intervention: One invitation letter (standard practice)
Number of subjects: 3144

Group type: EXPERIMENTAL
Intervention: One invitation letter plus a phone call (for women where a phone number was located)
Number of subjects: 3144
Study: 14648129

Group type: EXPERIMENTAL
Intervention: Short Rest Protocol (SRP) - 3 sets of 50 repetitions with 2 min total rest
Number of subjects: 8

Group type: COMPARATOR
Intervention: Long Rest Protocol (LRP) - 15 sets of 10 repetitions with 14 min total rest
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both protocols (SRP and LRP)
Number of subjects: 8
Study: 11763011

Group type: EXPERIMENTAL
Intervention: Cyproheptadine 16 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propranolol 80 mg/day
Number of subjects: 30
Study: 9395750

Group type: EXPERIMENTAL
Intervention: Recent pharmacological interventions for portal hypertension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current clinical research
Number of subjects: 0
Study: 8131380

Group type: COMPARATOR
Intervention: DSM-III
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: DSM-III-R
Number of subjects: 454
Study: 30885882

Group type: EXPERIMENTAL
Intervention: Portable gluten sensor device (Nima)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29082462

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with 940 nm diode laser, 7 sessions over 2 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (laser hand piece in 'off' mode)
Number of subjects: 19
Study: 26428200

Group type: EXPERIMENTAL
Intervention: Skin adhesive (SA)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Transcutaneous suture (TS)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both SA and TS
Number of subjects: 77
Study: 24567366

Group type: EXPERIMENTAL
Intervention: Docetaxel plus selumetinib
Number of subjects: 83

Group type: COMPARATOR
Intervention: Docetaxel plus placebo
Number of subjects: 83
Study: 22067809

Group type: EXPERIMENTAL
Intervention: SILCS diaphragm (single-sided gel delivery)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: SILCS diaphragm (double-sided gel delivery)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Gel applicator
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: SILCS diaphragm (single-sided and double-sided gel delivery)
Number of subjects: 36
Study: 20673054

Group type: EXPERIMENTAL
Intervention: 0.01% benzalkonium chloride (BAC) solution, applied three times daily for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo solution, applied three times daily for 12 weeks
Number of subjects: 20
Study: 19128624

Group type: EXPERIMENTAL
Intervention: IT dexamethasone injection
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (no further treatment)
Number of subjects: 52
Study: 16394299

Group type: EXPERIMENTAL
Intervention: Pentavalent human-bovine (WC3 strain) reassortant rotavirus vaccine
Number of subjects: 68038

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68038
Study: 12828801

Group type: EXPERIMENTAL
Intervention: Virgin Olive Oil 1 (VOO1)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Virgin Olive Oil 2 (VOO2)
Number of subjects: 31
Study: 10390266

Group type: EXPERIMENTAL
Intervention: Dexamethasone therapy (6 doses at 12-hour intervals starting at 24 to 48 hours of life)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 241
Study: 8695241

Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: G-CSF + TS
Number of subjects: 54
Study: 1738412

Group type: EXPERIMENTAL
Intervention: PGE1 infusion at 0.01 micrograms/min/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PGE1 infusion at 0.05 micrograms/min/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PGE1 infusion at 0.1 micrograms/min/kg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group receiving vehicle infusion without PGE1
Number of subjects: 6
Study: 6828682

Group type: EXPERIMENTAL
Intervention: Glucagon (0.05 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (0.05 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glucagon and Placebo
Number of subjects: 30
Study: 31607313

Group type: EXPERIMENTAL
Intervention: Low dose DAC 10 mg/(m2·d)×7 d
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal dose DAC 20 mg/(m2·d) ×5 d
Number of subjects: 51

Group type: COMPARATOR
Intervention: Low dose DAC+CAG (DAC 10 mg/(m2·d) d 1‐5, cytarabine 10 mg/(m2·d) q12h d 1‐7, aclaromycin 10 mg/d d 1‐4, G‐CSF 200 μg/(m2·d), d 1‐7)
Number of subjects: 51
Study: 29925916

Group type: EXPERIMENTAL
Intervention: TEA
Number of subjects: 42

Group type: COMPARATOR
Intervention: sham-TEA
Number of subjects: 42
Study: 27365226

Group type: EXPERIMENTAL
Intervention: Advice and physiotherapy (six 30-minute sessions over 4 months)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Advice (one-off session with advice booklets)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Advice and physiotherapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Advice
Number of subjects: 29
Study: 23495677

Group type: EXPERIMENTAL
Intervention: 200 mg/day phosphatidylserine (PS) for 2 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 22081981

Group type: EXPERIMENTAL
Intervention: Iron-rich bread (2.2 mg iron per 50 g slice) consumed at an average of 2.3 slices per day for 6 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 34
Study: 20110052

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.0 mg/m² IV on days 1, 4, 8, and 11 of two 21-day cycles plus ketoconazole 400 mg on days 6, 7, 8, and 9 of cycle 1
Number of subjects: 21

Group type: COMPARATOR
Intervention: Bortezomib 1.0 mg/m² IV on days 1, 4, 8, and 11 of two 21-day cycles without ketoconazole
Number of subjects: 21
Study: 17488902

Group type: EXPERIMENTAL
Intervention: Chloroquine 50 mg/kg
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Chloroquine 25 mg/kg
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Amodiaquine 15 mg/kg
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Chloroquine (general)
Number of subjects: 497
Study: 15174219

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 11744026

Group type: COMPARATOR
Intervention: Intermittent cross‐clamp fibrillation (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pharmacological preconditioning (GR79236X)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Number of subjects: 30
Study: 9626150

Group type: EXPERIMENTAL
Intervention: 1 mU/min insulin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 5 mU/min insulin
Number of subjects: 17

Group type: COMPARATOR
Intervention: vehicle (placebo)
Number of subjects: 17
Study: 7812199

Group type: EXPERIMENTAL
Intervention: 13-Cis retinoic acid (13-CRA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2508260

Group type: EXPERIMENTAL
Intervention: dDAVP followed by standard heparin
Number of subjects: 8

Group type: COMPARATOR
Intervention: dDAVP followed by saline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: standard heparin
Number of subjects: 8
Study: 808359

Group type: EXPERIMENTAL
Intervention: Chewable isosorbide dinitrate (CHIS), 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG), 0.6 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (P), two chewable tablets
Number of subjects: 8
Study: 30005170

Group type: EXPERIMENTAL
Intervention: Mother's Milk® herbal tea (test)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lemon verbena leaf (placebo)
Number of subjects: 60
Study: 28093356

Group type: EXPERIMENTAL
Intervention: PCT+LLLT
Number of subjects: 15

Group type: COMPARATOR
Intervention: LLLT alone
Number of subjects: 15
Study: 25438099

Group type: EXPERIMENTAL
Intervention: Conical implants with wide pitch (group 1)
Number of subjects: 20
Study: 24032271

Group type: EXPERIMENTAL
Intervention: 250 microg r-hCG
Number of subjects: 72

Group type: COMPARATOR
Intervention: 500 microg r-hCG
Number of subjects: 72
Study: 21807325

Group type: EXPERIMENTAL
Intervention: Enalapril and carvedilol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 19424093

Group type: EXPERIMENTAL
Intervention: 1.0% DHEA (Prasterone)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 16396728

Group type: EXPERIMENTAL
Intervention: High-velocity thrust manipulation
Number of subjects: 70
Study: 12764959

Group type: EXPERIMENTAL
Intervention: Alternating-pressure mattresses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overlays
Number of subjects: 0
Study: 10889124

Group type: EXPERIMENTAL
Intervention: 50 mg of orbofiban twice daily (50/50 group)
Number of subjects: 10288

Group type: EXPERIMENTAL
Intervention: 50 mg of orbofiban twice daily for 30 days followed by 30 mg of orbofiban twice daily (50/30 group)
Number of subjects: 10288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10288

Group type: EXPERIMENTAL
Intervention: Patients who underwent percutaneous coronary intervention
Number of subjects: 10288
Study: 8629915

Group type: EXPERIMENTAL
Intervention: Manual genital stimulation with a distracting task (78-minute protocol with 6-minute baselines and 12-minute testing conditions)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Masturbation after removal of the distracting task
Number of subjects: 20

Group type: COMPARATOR
Intervention: Performance of a distracting task with manual genital stimulation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Elimination of the distracting task
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall genital responses in able-bodied women
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall genital responses in women with SCI
Number of subjects: 20
Study: 1568517

Group type: EXPERIMENTAL
Intervention: Benzathine penicillin G (1,200,000 IU given intramuscularly)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Penicillin V (250 mg given orally twice daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Erythromycin stearate (250 mg given orally twice daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Roxithromycin (150 mg given orally once daily)
Number of subjects: 20
Study: 3839407

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tubocurarine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study: 31629439

Group type: EXPERIMENTAL
Intervention: PK Button
Number of subjects: 78

Group type: COMPARATOR
Intervention: Monopolar loop
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 78
Study: 29167892

Group type: EXPERIMENTAL
Intervention: Right-sided tumor location
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: Right-sided tumors with RAS mutations
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: Right-sided tumors with RAS and BRAF double wild type
Number of subjects: 1869

Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 1869
Study: 28963937

Group type: EXPERIMENTAL
Intervention: 30% of maximal voluntary force (MVC) for 30min
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 50% of maximal voluntary force (MVC) until task-failure
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: EMG activity during contractions
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Post hoc matched strength (n=10)
Number of subjects: 18
Study: 25679343

Group type: EXPERIMENTAL
Intervention: Elastic Therapeutic Taping (ETT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rigid Therapeutic Taping (RTT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No Tape
Number of subjects: 16
Study: 23195665

Group type: EXPERIMENTAL
Intervention: 60 seconds papillary balloon dilation (G60, n = 60)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 30 seconds papillary balloon dilation (G30, n = 64)
Number of subjects: 124
Study: 21075025

Group type: EXPERIMENTAL
Intervention: CRPS-IgG injected groups
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control-IgG injected groups
Number of subjects: 12
Study: 18003795

Group type: EXPERIMENTAL
Intervention: High-fat diet (HF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-fat diet (LF)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CCK-8 infusion (2 ng.kg(‐1).min(‐1))
Number of subjects: 10
Study: 16556903

Group type: EXPERIMENTAL
Intervention: Local blockade of nitric oxide and prostaglandins using nitro‐L‐arginine methyl ester and indomethacin during one‐legged dynamic knee‐extension exercise
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Local blockade of nitric oxide and prostaglandins
Number of subjects: 7
Study: 14980088

Group type: EXPERIMENTAL
Intervention: Telemedicine (TM)
Number of subjects: 62
Study: 10932513

Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin 0.3%
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cefazolin (50 mg/ml) and fortified gentamicin (14 mg/ml)
Number of subjects: 41
Study: 9298049

Group type: EXPERIMENTAL
Intervention: Topical aminocaproic acid
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Systemic aminocaproic acid
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 8393888

Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg) with 1 microgram/kg ovine CRH
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg) with 0.25 microgram ACTH-(1-24)
Number of subjects: 14
Study: 2437713

Group type: EXPERIMENTAL
Intervention: Clinagel
Number of subjects: 148

Group type: COMPARATOR
Intervention: Debrisan Paste
Number of subjects: 148
Study: 31806071

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 282
Study: 29304862

Group type: EXPERIMENTAL
Intervention: Veggie Van (VV) mobile produce market
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Veggie Van (VV) customers
Number of subjects: 142

Group type: COMPARATOR
Intervention: Non-customers (control)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Intervention participants
Number of subjects: 142
Study: 27580566

Group type: EXPERIMENTAL
Intervention: Vigabatrin treatment
Number of subjects: 65
Study: 24002623

Group type: EXPERIMENTAL
Intervention: CARVE-OUT (outsourced approach with telephone-based diabetes educator)
Number of subjects: 486

Group type: COMPARATOR
Intervention: CARVE-IN (clinic-based approach with clinic nurse)
Number of subjects: 486
Study: 23369169

Group type: EXPERIMENTAL
Intervention: Early surgical management
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 36
Study: 21690207

Group type: EXPERIMENTAL
Intervention: Strontium ranelate (SrRan)
Number of subjects: 34
Study: 19086331

Group type: EXPERIMENTAL
Intervention: Enteral lansoprazole (LODT) 30 mg mixed in 10 mL of water via a nasal gastric tube
Number of subjects: 19

Group type: COMPARATOR
Intervention: Intravenous lansoprazole (IV-L) 30 mg over 30 min
Number of subjects: 19
Study: 17073356

Group type: EXPERIMENTAL
Intervention: Immediately loaded implants
Number of subjects: 12

Group type: COMPARATOR
Intervention: Delayed loading implants (control)
Number of subjects: 12
Study: 14513918

Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10714402

Group type: EXPERIMENTAL
Intervention: Low-dose clonazepam (CZP) 0.02 mg/kg BW
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15